Heidelberg/Germany, September 14th – September 18th, 2015
The relevance of Health Technology Assessments (HTAs) for market access, pricing and reimbursement of health technologies has in-creased continuously over the last decades. The approaches adopted by HTA agencies to assess “value for money” vary greatly. This variance can hardly surprise as issues related to access to health care represent an area permeated with ideologically charged controversy. Unfortunately, many current courses in health economics do not address the background of this variance.
Thus, the Heidelberg Health Economics Summer School has been established to contribute to closing this gap, addressing the strengths, weaknesses, and potential of alternative economic evaluation para-digms, ranging from cost benefit analysis (CBA) and cost utility / effectiveness analysis (CUA/CEA) to more recently advocated social cost value analysis (CVA). Topical country-specific HTA case studies will be used to illustrate the policy relevance of these concepts, addressing examples such as ultra-orphan drugs, cancer and end-of-life treatments, as well as “personalized medicine”.
The Institute for Innovation & Valuation in Health Care in cooperation with the University of Heidelberg (Department for Public Health, Mannheim Medical Faculty) present a high–level program with these topics:
What are the conceptual foundations and limitations of the current health economic evaluation paradigm?
What are the implications of its actual use in the context of health Technology Assessments (HTAs) and decision-making on market access, pricing and reimbursement of medical technologies?